age1 is a venture capital firm that supports founder-led companies working on extending healthy human lifespan and addressing age-related diseases. They focus on exceptionally early-stage investments, from angel rounds to later stages, with a commitment to making a significant impact in the longevity field. Their goal is to catalyse groundbreaking solutions in therapeutics, tools, and technologies related to ageing.